315 related articles for article (PubMed ID: 30054698)
21. [Lys40(Ahx-DTPA-111In)NH2]exendin-4, a very promising ligand for glucagon-like peptide-1 (GLP-1) receptor targeting.
Wild D; Béhé M; Wicki A; Storch D; Waser B; Gotthardt M; Keil B; Christofori G; Reubi JC; Mäcke HR
J Nucl Med; 2006 Dec; 47(12):2025-33. PubMed ID: 17138746
[TBL] [Abstract][Full Text] [Related]
22. Exendin-4-based imaging in insulinoma localization: Systematic review and meta-analysis.
Shah R; Garg R; Majmundar M; Purandare N; Malhotra G; Patil V; Ramteke-Jadhav S; Lila A; Shah N; Bandgar T
Clin Endocrinol (Oxf); 2021 Aug; 95(2):354-364. PubMed ID: 33386617
[TBL] [Abstract][Full Text] [Related]
23. Molecular Imaging to the Surgeons Rescue: Gallium-68 DOTA-Exendin-4 Positron Emission Tomography-Computed Tomography in Pre-operative Localization of Insulinomas.
Pallavi UN; Malasani V; Sen I; Thakral P; Dureja S; Pant V; Gaikwad VS; Sabharwal A
Indian J Nucl Med; 2019; 34(1):14-18. PubMed ID: 30713372
[TBL] [Abstract][Full Text] [Related]
24. Morphologically 'invisible' proinsulin - secreting adenoma detected by Ga-68 Exendin-4 (GLP-1 Receptor) positron emission tomography/CT.
Werner C; Lupp A; Drescher R; Freesmeyer M; Mireskandari M; Stoykow C; Bauschke A; Müller UA
J Med Imaging Radiat Oncol; 2018 Jun; 62(3):370-374. PubMed ID: 29399966
[TBL] [Abstract][Full Text] [Related]
25.
Sakaki K; Murakami T; Fujimoto H; Shimizu Y; Miyake KK; Otani D; Kiyobayashi S; Okada T; Fujimoto M; Hakata T; Yamauchi I; Shimada K; Shimizu H; Nagai K; Nakamoto Y; Inagaki N
Front Endocrinol (Lausanne); 2023; 14():1245573. PubMed ID: 37720533
[TBL] [Abstract][Full Text] [Related]
26. Development of
Kimura H; Matsuda H; Ogawa Y; Fujimoto H; Toyoda K; Fujita N; Arimitsu K; Hamamatsu K; Yagi Y; Ono M; Inagaki N; Saji H
Bioorg Med Chem; 2017 Feb; 25(4):1406-1412. PubMed ID: 28089587
[TBL] [Abstract][Full Text] [Related]
27. Protocol for Clinical GLP-1 Receptor PET/CT Imaging with [
Tokgöz S; Boss M; Prasad S; Shah P; Laverman P; van Riel M; Gotthardt M
Methods Mol Biol; 2023; 2592():143-153. PubMed ID: 36507990
[TBL] [Abstract][Full Text] [Related]
28. Radioiodinated Exendin-4 Is Superior to the Radiometal-Labelled Glucagon-Like Peptide-1 Receptor Probes Overcoming Their High Kidney Uptake.
Läppchen T; Tönnesmann R; Eersels J; Meyer PT; Maecke HR; Rylova SN
PLoS One; 2017; 12(1):e0170435. PubMed ID: 28103285
[TBL] [Abstract][Full Text] [Related]
29. 68Ga-DOTA-Exendin PET-MRI Fusion Imaging in a Case of Insulinoma.
Sood A; Basher RK; Kang M; Shukla J; Behera A; Walia R; Nada R; Mittal BR; Bhattacharya A
Clin Nucl Med; 2019 Jul; 44(7):e428-e430. PubMed ID: 31107750
[TBL] [Abstract][Full Text] [Related]
30. 68Ga DOTA-Exendin PET/CT for Detection of Insulinoma in a Patient With Persistent Hyperinsulinemic Hypoglycemia.
Parihar AS; Vadi SK; Kumar R; Mittal BR; Singh H; Bal A; Walia R; Shukla J; Sinha SK
Clin Nucl Med; 2018 Aug; 43(8):e285-e286. PubMed ID: 29877881
[TBL] [Abstract][Full Text] [Related]
31. Pre-clinical evaluation of [(68)Ga]Ga-DO3A-VS-Cys(40)-Exendin-4 for imaging of insulinoma.
Selvaraju RK; Velikyan I; Asplund V; Johansson L; Wu Z; Todorov I; Shively J; Kandeel F; Eriksson B; Korsgren O; Eriksson O
Nucl Med Biol; 2014 Jul; 41(6):471-6. PubMed ID: 24857864
[TBL] [Abstract][Full Text] [Related]
32. 18F-radiolabeled GLP-1 analog exendin-4 for PET/CT imaging of insulinoma in small animals.
Wu H; Liang S; Liu S; Pan Y; Cheng D; Zhang Y
Nucl Med Commun; 2013 Jul; 34(7):701-8. PubMed ID: 23652208
[TBL] [Abstract][Full Text] [Related]
33. Development of an
Iikuni S; Kamei I; Ohara T; Watanabe H; Ono M
Mol Pharm; 2022 Mar; 19(3):1019-1027. PubMed ID: 35138111
[TBL] [Abstract][Full Text] [Related]
34. Insulinoma imaging with glucagon-like peptide-1 receptor targeting probe (18)F-FBEM-Cys (39)-exendin-4.
Xu Y; Pan D; Xu Q; Zhu C; Wang L; Chen F; Yang R; Luo S; Yang M
J Cancer Res Clin Oncol; 2014 Sep; 140(9):1479-88. PubMed ID: 24838847
[TBL] [Abstract][Full Text] [Related]
35. Synthesis and evaluation of optical and PET GLP-1 peptide analogues for GLP-1R imaging.
Behnam Azad B; Rota V; Yu L; McGirr R; St Amant AH; Lee TY; Dhanvantari S; Luyt LG
Mol Imaging; 2015; 14():. PubMed ID: 25762192
[TBL] [Abstract][Full Text] [Related]
36. Structure-Activity Relationships and Pharmacokinetics of
Iikuni S; Ohara T; Watanabe H; Ono M
Mol Pharm; 2022 Aug; 19(8):2832-2839. PubMed ID: 35757958
[TBL] [Abstract][Full Text] [Related]
37. Glucagon-like peptide-1 versus somatostatin receptor targeting reveals 2 distinct forms of malignant insulinomas.
Wild D; Christ E; Caplin ME; Kurzawinski TR; Forrer F; Brändle M; Seufert J; Weber WA; Bomanji J; Perren A; Ell PJ; Reubi JC
J Nucl Med; 2011 Jul; 52(7):1073-8. PubMed ID: 21680696
[TBL] [Abstract][Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]